TherapeuticsMD (TXMD) Competitors $1.37 +0.03 (+2.24%) (As of 01:52 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TXMD vs. CUE, CELU, ALRN, INCR, CRVO, XFOR, ATRA, ENTX, OPTN, and MURAShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Cue Biopharma (CUE), Celularity (CELU), Aileron Therapeutics (ALRN), InterCure (INCR), CervoMed (CRVO), X4 Pharmaceuticals (XFOR), Atara Biotherapeutics (ATRA), Entera Bio (ENTX), OptiNose (OPTN), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. TherapeuticsMD vs. Cue Biopharma Celularity Aileron Therapeutics InterCure CervoMed X4 Pharmaceuticals Atara Biotherapeutics Entera Bio OptiNose Mural Oncology Cue Biopharma (NASDAQ:CUE) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Which has more volatility & risk, CUE or TXMD? Cue Biopharma has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Which has stronger valuation & earnings, CUE or TXMD? TherapeuticsMD has lower revenue, but higher earnings than Cue Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCue Biopharma$5.49M9.57-$50.73M-$0.90-1.20TherapeuticsMD$1.30M12.15-$10.28MN/AN/A Does the media prefer CUE or TXMD? In the previous week, Cue Biopharma had 5 more articles in the media than TherapeuticsMD. MarketBeat recorded 9 mentions for Cue Biopharma and 4 mentions for TherapeuticsMD. Cue Biopharma's average media sentiment score of 0.27 beat TherapeuticsMD's score of -0.35 indicating that Cue Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of CUE or TXMD? 35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 12.3% of Cue Biopharma shares are owned by insiders. Comparatively, 2.3% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in CUE or TXMD? TherapeuticsMD received 240 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 59.38% of users gave TherapeuticsMD an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote. CompanyUnderperformOutperformCue BiopharmaOutperform Votes14652.33% Underperform Votes13347.67% TherapeuticsMDOutperform Votes38659.38% Underperform Votes26440.62% Is CUE or TXMD more profitable? TherapeuticsMD has a net margin of -207.77% compared to Cue Biopharma's net margin of -468.02%. TherapeuticsMD's return on equity of -14.08% beat Cue Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Cue Biopharma-468.02% -156.38% -88.07% TherapeuticsMD -207.77%-14.08%-9.61% Do analysts prefer CUE or TXMD? Cue Biopharma presently has a consensus target price of $5.00, suggesting a potential upside of 362.96%. Given Cue Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Cue Biopharma is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00TherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCue Biopharma beats TherapeuticsMD on 9 of the 16 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.80M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.5095.1214.22Price / Sales12.15375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book0.5810.276.976.37Net Income-$10.28M$153.22M$118.73M$225.56M7 Day Performance-6.16%-1.19%-1.22%-0.02%1 Month Performance-13.29%-6.71%-3.07%2.04%1 Year Performance-50.81%32.39%32.52%28.00% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD0.6657 of 5 stars$1.37+2.2%N/A-54.1%$15.80M$1.30M0.00420Analyst ForecastCUECue Biopharma4.4488 of 5 stars$1.08-0.9%$5.00+363.0%-55.3%$52.53M$5.49M-1.2160CELUCelularity0.5388 of 5 stars$2.79-5.1%N/A+42.7%$61.35M$22.77M0.00220News CoverageALRNAileron Therapeutics3.5795 of 5 stars$2.83+2.5%$19.00+571.4%+46.0%$61.33MN/A-0.829INCRInterCure1.2529 of 5 stars$1.32-1.0%N/A+16.0%$60.15M$96.61M0.00350Positive NewsGap UpCRVOCervoMed1.3363 of 5 stars$9.70+0.6%$53.60+452.6%-1.8%$59.85M$7.14M0.004XFORX4 Pharmaceuticals4.2011 of 5 stars$0.35+2.7%$2.88+722.1%-57.4%$59.64MN/A0.0080Analyst RevisionATRAAtara Biotherapeutics3.8259 of 5 stars$10.31-3.5%$16.67+61.7%-23.4%$59.39M$8.57M0.00165ENTXEntera Bio2.0488 of 5 stars$1.66+6.8%$10.00+504.2%+112.3%$59.22M$130,000.00-6.0820OPTNOptiNose4.0578 of 5 stars$0.39+5.7%$3.00+673.6%-69.2%$58.49M$70.99M-1.31190Gap UpMURAMural Oncology3.2807 of 5 stars$3.38+0.3%$16.00+373.4%N/A$57.53MN/A0.00119Analyst RevisionPositive News Related Companies and Tools Related Companies Cue Biopharma Alternatives Celularity Alternatives Aileron Therapeutics Alternatives InterCure Alternatives CervoMed Alternatives X4 Pharmaceuticals Alternatives Atara Biotherapeutics Alternatives Entera Bio Alternatives OptiNose Alternatives Mural Oncology Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TXMD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
